-
Mashup Score: 5Can these drugs stop a COVID infection in its tracks? Seattle researchers are on the forefront of new treatments - 2 year(s) ago
The world of COVID drugs has come a long way since March 2020, leading to new use of antivirals around the country. Now, a Seattle scientist is looking at what’s next.
Source: The Seattle TimesCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series - 2 year(s) ago
Significant advances have been made in the diagnosis and treatment of SARS-CoV-2 infection. Nevertheless, it seems that the virus and its mutations will be present in our lives for the years to come.1 People living with systemic rheumatic diseases (SRDs),2 especially those with certain characteristics and comorbidities such as coexisting lung disease, male gender and increasing age, are at…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
Excellent outcome of oral antivirals (#molnupiravir and #nirmatrelvir/ritonavir combination) in systemic #rheumatic diseases patients at risk for development of severe #COVID-19, without any safety signals https://t.co/OjdcfEpzms
-
-
Mashup Score: 2Can these drugs stop a COVID infection in its tracks? Seattle researchers are on the forefront of new treatments - 2 year(s) ago
The world of COVID drugs has come a long way since March 2020, leading to new use of antivirals around the country. Now, a Seattle scientist is looking at what’s next.
Source: The Seattle TimesCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #COVID antiviral #molnupiravir received EUA back in December 2021. Results from a trial led by Fred Hutch's Dr. Elizabeth Duke could change that, making the pill the first FDA-approved COVID post-exposure prophylaxis available to the general public. https://t.co/ij2W5qwkCP
-
-
Mashup Score: 0CCRC Clinical Studies - 2 year(s) ago
Find information on the clinical trials and novel interventions currently being studied at the COVID-19 Clinical Research Center at Fred Hutch.
Source: Fred HutchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Duke's trial for #molnupiravir as a preventive drug is still underway and accepting eligible participants through July — hopefully in time to get results by the fall, she said. Learn more: https://t.co/bABbSeWaUc
-
-
Mashup Score: 5Secondary Analysis of Molnupiravir Trial for Shows Additional Benefits for COVID-19 Patients - 2 year(s) ago
Merck’s antiviral drug molnupiravir may benefit nonhospitalized patients with mild or moderate COVID-19, according to a secondary analysis of phase 3 clinical trial data.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
Investigators with @Merck demonstrate reduced need for respiratory interventions among #COVID19 patients who took #molnupiravir https://t.co/EbCIHKNSRD
-
-
Mashup Score: 5
Background: In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progression to severe disease. Objective: To identify other potential clinical benefits of molnupiravir versus placebo. Design: Secondary analysis of the randomized, double-blind, placebo-controlled phase 3…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#ICYMI: a new analysis of MOVe-OUT trial has found that #Molnupiravir-treated participants had a decreased need for respiratory interventions and fewer #COVID19-related acute care visits: https://t.co/XHdc3odwEz https://t.co/YddtKYehe4
-
-
Mashup Score: 4Secondary Analysis of Molnupiravir Trial for Shows Additional Benefits for COVID-19 Patients - 2 year(s) ago
Merck’s antiviral drug molnupiravir may benefit nonhospitalized patients with mild or moderate COVID-19, according to a secondary analysis of phase 3 clinical trial data.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
Dr. Matthew Johnson of @Merck led a secondarily analysis of data from phase 3 trials of #molnupiravir finding additional benefits of the antiviral drug. https://t.co/EbCIHKNSRD
-
-
Mashup Score: 1
Background: In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progression to severe disease. Objective: To identify other potential clinical benefits of molnupiravir versus placebo. Design: Secondary analysis of the randomized, double-blind, placebo-controlled phase 3…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A new analysis of MOVe-OUT trial has found that #Molnupiravir-treated participants had a decreased need for respiratory interventions and fewer #COVID19-related acute care visits: https://t.co/X4dETN1Nuu https://t.co/xdKRozgNza
-
-
Mashup Score: 3News Scan for Apr 01, 2022 - 2 year(s) ago
Molnupiravir reduces COVID-19 symptoms, virus by day 3, data showThree new studies to be presented at the upcoming European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) conference at the end of the month demonstrate benefits of the antiviral molnupiravir against COVID-19 infections, including evidence that Merck’s pill reduces symptoms of the…
Source: CIDRAPCategories: Infectious Disease, Latest HeadlinesTweet-
RT @NCThirdAge: @CIDRAP: Antiviral #Molnupiravir reduces COVID-19 symptoms, virus by day 3, data show https://t.co/xEaLtsp8fM
-
-
Mashup Score: 2Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Emergency Medicine, Latest HeadlinesTweet-
#Ritonavir/nirmatrelvir & #molnupiravir were approved by the @US_FDA to treat #COVID19, and @poisonreview reviews how to use these oral drugs. #FOAMtox #FOAMed https://t.co/XRJ1dU8njJ https://t.co/Ydw8V13D08
-
The #COVID antiviral #molnupiravir received EUA back in December 2021. Results from a trial led by Fred Hutch's Dr. Elizabeth Duke could change that, making the pill the first FDA-approved COVID post-exposure prophylaxis available to the general public. https://t.co/ij2W5qwkCP